Skip to main content

Zygem to Sell Rubicon Kits Down Under

NEW YORK (GenomeWeb News) – Zygem will market Rubicon Genomics' PicoPlex single-cell amplification kits in Australia and New Zealand, under a non-exclusive agreement, Rubicon said today.

Rubicon's kits are used to amplify small clinical samples into large amounts of pure DNA, and they are licensed and sold to clinical markets for pre-implantation and prenatal testing, cancer testing, and for making diagnostics.

DNA amplified using the PicoPlex can be analyzed using qPCR, microarrays, and next-generation sequencing technologies for either research or diagnostic purposes, and it represents genomic sequencings without the common problem of allele dropouts, Ann Arbor, Mich.-based Rubicon said.

Zygem makes DNA and RNA extraction and detection products and enzymes used in molecular biology and diagnostic applications. Its customers include those involved in basic research, forensics, clinical diagnostics, and agriculture.

"The PicoPlex technology nicely complements Zygem's advanced DNA extraction products and we are looking forward to bringing this cutting-edge technology to the markets we serve in Australia and New Zealand," Paul Kinnon, CEO of Zygem, said in a statement.

The Scan

Possibly as Transmissible

Officials in the UK say the B.1.617.2 variant of SARS-CoV-2 may be as transmitted as easily as the B.1.1.7 variant that was identified in the UK, New Scientist reports.

Gene Therapy for SCID 'Encouraging'

The Associated Press reports that a gene therapy appears to be effective in treating severe combined immunodeficiency syndrome.

To Watch the Variants

Scientists told US lawmakers that SARS-CoV-2 variants need to be better monitored, the New York Times reports.

Nature Papers Present Nautilus Genome, Tool to Analyze Single-Cell Data, More

In Nature this week: nautilus genome gives peek into its evolution, computational tool to analyze single-cell ATAC-seq data, and more.